Platinum-Resistant Advanced Ovarian Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Platinum-Resistant Advanced Ovarian Cancer Market Outlook

Thelansis’s “Platinum-Resistant Advanced Ovarian Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Platinum-Resistant Advanced Ovarian Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Platinum-Resistant Advanced Ovarian Cancer Overview

Platinum-resistant ovarian cancer, characterized by a grim prognosis and limited treatment choices, represents a challenging subtype of ovarian cancer. It is identified by the reappearance of the disease within six months after a platinum-based chemotherapy regimen is completed. The development of resistance to platinum compounds involves intricate mechanisms, and approximately 25% of women with ovarian cancer naturally exhibit resistance to platinum treatments. While many patients initially respond well to frontline platinum therapy, they often experience disease recurrence and gradually acquire resistance over time. For the past three decades, platinum-based chemotherapy has stood as the standard care for ovarian cancer. Nevertheless, some patients eventually develop resistance to platinum in recurrent cases of the disease. Currently, the primary therapeutic approach for platinum-resistant recurrent ovarian cancer patients involves systemic chemotherapy, including agents like polyethylene glycol liposome doxorubicin (PLD) and topotecan. The effectiveness of these treatments typically ranges from 10% to 30%. Additional chemotherapy regimens encompass gemcitabine, etoposide, ifosfamide, docetaxel, and vinorelbine.

• The median overall survival for women grappling with platinum-resistant ovarian cancer is approximately 12 months.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: